Navigation Links
Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
Date:10/12/2011

ALISO VIEJO, Calif., Oct. 12, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that pseudobulbar affect (PBA) prevalence data from stroke survivors will be highlighted at the 88th Annual Meeting of the American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in Atlanta, GA.

Following are details about the data presentation at ACRM/ASNR Progress in Rehabilitation Research:

Title: Pseudobulbar Affect in Stroke: A National Stroke Association Survey
Program Number: 0025
Presentation Date/Time: Thursday, October 13, 2011 5:00-7:00 p.m. EST & Friday October 14, 2011 4:30-6:45 p.m. EST

About PBA

Patients suffering from existing neurological disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of crying and/or laughing. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition-such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit www.PBAinfo.org.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals to Participate in Two Investor Conferences
2. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
3. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
4. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
5. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
6. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
7. Avanir Pharmaceuticals Provides Update on European Regulatory Filing for NUEDEXTA
8. Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
9. Avanir Pharmaceuticals Reports Fiscal 2011 Second Quarter Results
10. Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs
11. Avanir Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ) (TSX: ... executive management will participate in the RBC Capital Markets ... Adrian Adams , Chief Executive Officer, will provide ... time on Wednesday, February 22, 2017. A ... be accessed from the Investors section of the Aralez ...
(Date:2/16/2017)... WOONSOCKET, R.I. , Feb. 16, 2017  Newly ... CVS ) Research Institute emphasizes the role a private ... improving public health. The study, published online today in ... that the Company,s decision to remove tobacco from all ... across all retail settings with an even greater impact ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 , ... ... source of disruptive innovation in the industry, according to the recent NEJM Catalyst ... based on surveys of the NEJM Catalyst Insights Council, a qualified group of ...
(Date:2/18/2017)... CA (PRWEB) , ... February 18, 2017 , ... ... paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 ... and so many other applications. Users can pick and choose from hand-crafted ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... WASHINGTON (PRWEB) , ... February 17, 2017 , ... ... communities by fall 2017 season , Trinity Health and the U.S. Soccer Foundation ... for Success program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring ...
Breaking Medicine News(10 mins):